URGENT:COVID prophylaxis | Vitamin D | Latest research | NIH | CDC | Worldometer
Albiglutide is a recombinant DNA produced polypeptide analogue of human glucagon-like peptide-1 (GLP-1) which is used in combination with diet and exercise in the therapy of type 2 diabetes, either alone or in combination with other antidiabetic agents.
Liver safety of Albiglutide
There have been no published reports of hepatotoxicity attributed to albiglutide therapy.
Mechanism of action of Albiglutide
Albiglutide (al" bi gloo' tide) is a glucagon-like peptide-1 (GLP-1) analogue (also called a GLP-1 receptor agonist) that acts like the native gastrointestinal hormone (incretin) to increase insulin secretion. Albiglutide reproduces the activity of GLP-1, binding to specific receptors on pancreatic beta cells and increasing insulin secretion, which can lead to improvement of glycemic control in patients with type 2 diabetes. Albiglutide is a recombinant DNA-produced polypeptide consisting of two 30-amino acid sequence molecules that are fused as a tandem repeat. The amino acid sequence of albiglutide is >90% homologous to endogenous human GLP-1(7-37) and differs only by a single amino acid substitution, which makes it resistant to degradation by dipeptidyl peptidase 4 (DPP4). The half-life of albiglutide is further prolonged by coupling of two recombinant molecules to human serum albumin. Albiglutide, like other GLP-1 analogues, must be given parenterally, but it has a half-life of 5 days which allows for once weekly dosing.
FDA approval information for Albiglutide
Albiglutide was approved for use in the United States in 2014, and current indications are for management of glycemic control in adults with type 2 diabetes in combination with diet and exercise, with or without other oral hypoglycemic agents.
Dosage and administration for Albiglutide
Albiglutide is available under the brand name Tanzeum in a powder for reconstitution and is given by subcutaneous injection in an initial dose of 30 mg once weekly, which can be increased to 50 mg once weekly. Albiglutide is generally well tolerated, but side effects can be dose limiting and include injection site reactions, diarrhea, nausea, vomiting, dizziness, headache, fatigue and hypoglycemia. Rare adverse events include pancreatitis and hypersensitivity reactions.
- Alpha-Glucosidase Inhibitors
- Incretin-Based Drugs
- Metiglinide Analogues
- Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitors